Natixis’s Telix Pharmaceuticals TLX Stock Holding History

Natixis’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$127K	Buy	+10,999	New	+$112K	﹤0.01%	979

Other funds holding TLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Natixis's TLX Position: Q2 2026 in Review

Natixis opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 10,999 shares worth $127K. The stake represents ﹤0.01% of the portfolio and ranks #979 among its holdings.

61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

Natixis held 10,999 shares of Telix Pharmaceuticals worth $127K as of Q2 2026.
Telix Pharmaceuticals was a new Natixis position in Q2 2026.
Telix Pharmaceuticals made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #979 holding.
61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.